Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant tech. company of fraudulent practices, including kickbacks, billing fraud, ...

Shares of TransMedics (TMDX) are falling after Scorpion Capital revealed its short position on the company Friday. The ...

Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...

Scorpion Capital said in a newly-issued short report that in “20 years of shorting, TransMedics (TMDX) is the most extreme and grotesque ...

NDAQ:TMDX) Kehoe Law Firm, P.C. Securities Investigation on Behalf of Investors of TransMedics Group Stock Following Critical Report - NASDAQ: TMDX ...

EST TransMedics (TMDX) down 10% to $65.39 after Scorpion Capital short reportStay Ahead of the Market:Discover outperforming stocks and ...

The report further alleges that TransMedics has been involved in kickbacks, billing fraud, unreported device failures, and ...

TransMedics is a commercial-stage medical technology company working on organ transplant therapy. Check out more about the ...

TransMedics TMDX shares rallied 10.1% in the last trading session to close at $159.14. This move can be attributable to notable volume with a higher number of shares being traded than in a typical ...

TransMedics Gr TMDX has outperformed the market over the past 5 years by 16.16% on an annualized basis producing an average annual return of 29.7%. Currently, TransMedics Gr has a market ...

Despite a Q3 revenue miss and temporary issues, TransMedics' long-term growth prospects remain strong, with plans for ...

Dey, Aiyesha, Jonas Heese, Suraj Srinivasan, and Annelena Lobb. "Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues." Harvard Business School Case 123-037, October 2022.